Albertsons' retail media division opens its first NYC office and unveils a new logo, signaling a significant expansion and strategic push to deepen ties with advertisers and agencies in the competitive retail media landscape.
The Rafah border crossing between Gaza and Egypt has partially reopened under the terms of the US-brokered ceasefire, permitting a limited number of medical evacuations for the first time in nearly two years, as tens of thousands await passage.
Pharmaceutical giant Eli Lilly enters a strategic collaboration potentially worth up to $1.93 billion with biotech firm Repertoire Immune Medicines, aiming to develop precision treatments for autoimmune diseases that move beyond broad immunosuppression.
Wells Fargo lowered its price target on UnitedHealth Group (UNH) following its Q4 report and a disappointing Medicare rate proposal from regulators, highlighting pressures on the healthcare giant's key growth engine.
Eli Lilly's CEO sees Medicare's new policy covering obesity treatments as a pivotal moment, poised to unlock access for millions of beneficiaries to its incoming oral drug, orforglipron, and intensify the market battle with Novo Nordisk.
Millions rely on Medicare, yet common misunderstandings about its coverage rules and costs can lead to significant financial shocks in retirement. We clarify three critical areas where assumptions often prove wrong.
BeOne Medicines extends its collaboration with quantitative systems pharmacology firm InSysBio, aiming to optimize clinical trial dosing and mitigate cytokine release syndrome risks across its broad portfolio of 15 novel oncology assets.
Despite underperforming the broader market since August 2025, insurance marketplace platform MediaAlpha (MAX) exhibits robust fundamentals—including sustained sales growth, expanding cash flow margins, and rising returns on capital—that could signal significant upside potential for patient investors.
Russia's former president Dmitry Medvedev cautions that the potential lapse of the last major U.S.-Russia nuclear arms treaty without a successor could plunge the world into an unprecedented era of strategic instability unseen since the Cold War.
CONMED's latest earnings reveal a strategic pivot towards higher-growth surgical platforms, moving away from slower gastroenterology lines. While sales climbed, profitability softened, setting the stage for a crucial transition year as the market weighs the company's reset valuation against its ambitious 2026 roadmap.
In a recent interview, Russia's Security Council Deputy Chairman Dmitry Medvedev forecast a swift end to the Ukraine war, while emphasizing that preventing further escalation remains the ultimate objective.
BeOne Medicines (NasdaqGS: ONC) has significantly expanded its strategic partnership with systems biology firm InSysBio. The deepened collaboration aims to leverage advanced mechanistic modeling to de-risk clinical trial design, with a particular focus on optimizing dosing and preempting safety challenges like cytokine release syndrome in oncology studies.
South Dakota Governor Kristi Noem faces intense backlash from within the conservative base after stating armed protesters cannot be considered 'peaceful,' with critics accusing her of betraying core constitutional principles.
BeOne Medicines (ONC) presents a complex picture for investors, with recent short-term volatility contrasting sharply with strong long-term returns. As the stock trades around $340, analysts debate whether its current price fully reflects the ambitious growth narrative in its oncology pipeline.
A key ally of Prime Minister Narendra Modi has proposed legislation to prohibit social media access for children under 16, framing the move as a response to digital addiction and the exploitation of Indian user data by foreign tech giants, amid a growing global regulatory push.
Tilray Brands deepens its commitment to Europe's regulated medical cannabis sector with the launch of Tilray Medical Italia, a strategic venture with local partner Molteni Farmaceutici. The move comes as the company seeks to stabilize its growth narrative amid significant stock market volatility.
Medtronic's expanded partnership with Mindray integrates its monitoring technologies into ASC-focused platforms, a strategic move to embed itself in a high-growth segment while analysts debate its impact on the broader investment thesis.
Stryker Corporation's latest earnings report, driven by its MedSurg, Neurotechnology divisions and the Mako surgical robot, has reignited investor debate. With shares near $370 and a bullish fair value estimate of $427, analysts are weighing robust growth against a premium valuation.
While fully autonomous robotic surgeons remain on the horizon, the foundational technology and data ecosystems being built today are setting the stage for a transformative shift. Two industry giants, Intuitive Surgical and Medtronic, offer investors distinct pathways to capitalize on this evolving landscape.
New CMS reimbursement rates are pressuring Medicare Advantage profits, sending shares of Humana and CVS Health lower. We analyze whether the sell-off presents a buying opportunity for dividend investors or signals deeper structural challenges.
